Literature DB >> 15897778

Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein.

Qing-Feng Yin1, Yan Xiong.   

Abstract

This study was designed to investigate whether glycated bovine serum albumin (AGE-BSA) inhibits dimethylarginine dimethylaminohydrolase (DDAH) activity to contribute to its adverse effect on endothelium-dependent relaxation in rat aorta, and whether pravastatin reverses the inhibition of DDAH activity and endothelial dysfunction induced by AGE-BSA. Endothelium-dependent relaxation of aortic rings was measured by isometric tension recording, and DDAH activity, and the contents of nitrite/nitrate as well as malondialdehyde (MDA) in aortic tissue were determined after exposure of Sprague-Dawley rat aorta to AGE-BSA (1.70 mmol/L) for 60 minutes in the presence or absence of pravastatin. In comparison with control, both endothelium-dependent relaxation and DDAH activity (0.032 +/- 0.002 versus 0.095 +/- 0.003 U/g protein, n = 5, P < 0.01) were significantly inhibited in isolated rat aorta after exposure to AGE-BSA, which was accompanied by decreases of nitrite/nitrate contents and elevations of MDA levels in aorta. Treatment with pravastatin (1 mmol/L) not only prevented the inhibition of endothelial function but also reversed the decrease of DDAH activity induced by AGE-BSA and normalized the alterations in nitrite/nitrate and MDA contents. Similar effects were observed when rat aorta exposed to AGE-BSA in the presence of antioxidant pyrrolidine dithiocharbamate (PDTC, 30 micromol/L) or protein kinase C inhibitor chelerythrine (1 micromol/L). These results suggested that decreased DDAH activity may be involved in endothelial dysfunction of rat aorta induced by AGE-BSA, and that pravastatin restores DDAH activity and endothelium-dependent relaxation after aorta exposure to AGE-BSA, which may be secondary to its antioxidative effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897778     DOI: 10.1097/01.fjc.0000159642.44523.7f

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Determination of dimethylarginine dimethylaminohydrolase activity in the kidney.

Authors:  Y-L Tain; C Baylis
Journal:  Kidney Int       Date:  2007-07-25       Impact factor: 10.612

Review 2.  [Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor].

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 3.  Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Yuzo Yano; Taku Tsunoda; Takashi Ikawa; Toshihiro Matsuo; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Exp Med       Date:  2015-05-20

Review 4.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

5.  SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation.

Authors:  Takafumi Toyohara; Takehiro Suzuki; Ryo Morimoto; Yasutoshi Akiyama; Tomokazu Souma; Hiromi O Shiwaku; Yoichi Takeuchi; Eikan Mishima; Michiaki Abe; Masayuki Tanemoto; Satohiro Masuda; Hiroaki Kawano; Koji Maemura; Masaaki Nakayama; Hiroshi Sato; Tsuyoshi Mikkaichi; Hiroaki Yamaguchi; Shigefumi Fukui; Yoshihiro Fukumoto; Hiroaki Shimokawa; Ken-ichi Inui; Tetsuya Terasaki; Junichi Goto; Sadayoshi Ito; Takanori Hishinuma; Isabelle Rubera; Michel Tauc; Yoshiaki Fujii-Kuriyama; Hikaru Yabuuchi; Yoshinori Moriyama; Tomoyoshi Soga; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

Review 6.  Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Authors:  Seiji Ueda; Sho-Ichi Yamagishi; Yuriko Matsumoto; Kei Fukami; Seiya Okuda
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

7.  Mechanisms underlying suppression of noradrenaline-induced contraction by prolonged treatment with advanced glycation end-products in organ-cultured rat carotid artery.

Authors:  Takayuki Matsumoto; Keisuke Takayanagi; Mihoka Kojima; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2020-01-18       Impact factor: 3.657

8.  Nitric oxide manipulation: a therapeutic target for peripheral arterial disease?

Authors:  Gareth Williams; Xu Shi-Wen; David Abraham; Sadasivam Selvakumar; Daryll M Baker; Janice C S Tsui
Journal:  Cardiol Res Pract       Date:  2012-03-20       Impact factor: 1.866

Review 9.  Asymmetric dimethyarginine as marker and mediator in ischemic stroke.

Authors:  Shufen Chen; Na Li; Milani Deb-Chatterji; Qiang Dong; Jan T Kielstein; Karin Weissenborn; Hans Worthmann
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

10.  Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; Min Jung Lee; So Mi Seol; Yun Mi Kim; Yoo La Lee; Hyun Sik Kim; Min-Seon Kim; Joong-Yeol Park
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.